Tag Archives: The Stem Cell Blog

CEOs of top gene-editing firms got huge compensation hikes last year – Boston Business Journal

Continue reading

2017-04-27 NEWS

Boston Business Journal

CEOs of top gene-editing firms got huge compensation hikes last year
Boston Business Journal
It’s no secret that the burgeoning field of gene-editing — a method of cutting out and replacing part of a gene — has generated serious buzz in the biotech world lately. New scientific tools like CRISPR/Cas9 have the potential to revolutionize the
CRISPR Therapeutics and Casebia Therapeutics Announce Exclusive Development and Option Agreement with …GlobeNewswire (press release)
CRISPR Therapeutics, Casebia ink AAV deal with StrideBio; Puma gets an AdComm date; Merrimack names new R&D …Endpoints News
Crispr Therapeutics AG (CRSP) Given Consensus Recommendation of “Strong Buy” by AnalystsThe Cerbat Gem
Sports Perspectives –Benchmark Monitor –Chaffey Breeze
all 26 news articles »
Continue reading

2017-04-27 NEWS

Jewish News

Stem cell donor pays ‘tiny price to save someone’s life’
Jewish News
After further testing, he was told there was a one in four chance of him being able to help an anonymous male patient and last month was confirmed as a definite match. Gould underwent four days of injections to prompt his body to produce more stem cells.

Continue reading

2017-04-27 NEWS

PLoS Blogs (blog)

Pulling the Plug on the First Gene Therapy Drug
PLoS Blogs (blog)
2017 is supposed to be the year that FDA finally approves a gene therapy. But last week, the company behind the first approved gene therapy in Europe, uniQure.com, announced that it won’t “pursue the renewal of marketing authorization” that expires …

Continue reading

2017-04-27 NEWS

STAT

CRISPR.com was for sale, and you won’t guess who bought it
STAT
Though perhaps not as lucrative as the technology itself, the domain could have been advantageous for CRISPR-focused companies — Editas Medicine, CRISPR Therapeutics, Intellia — that might have seen a clever branding opportunity. But until recently …

and more »